2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6e6,Uncomplicated urinary tract infections (uUTIs) can cause distressing symptoms seriously impacting daily activities. Early symptom relief during treatment, though fundamental to patients, is often overlooked in clinical trials. Gepotidacin, a new antibacterial agent, was noninferior to the first-line treatment nitrofurantoin in two randomized controlled trials (EAGLE-2 [NCT04020341] and EAGLE-3 [NCT04187144]). The current analysis utilized pooled data from these two trials to evaluate symptom responses during and after treatment in participants with uUTI. Participants were aged ≥12 years with at least two uUTI symptoms, urinary nitrite and/or pyuria, and no complicating factors. Participants were randomized 1:1 to oral gepotidacin (1500 mg) or nitrofurantoin (100 mg), both taken twice daily for 5 days. At baseline (Day 1), on-therapy (OT; Day 2-4), and test-of-cure (TOC; Day 10-13) visits, urinary symptoms were assessed (0-3; none-severe) from which a total score (0-12) was derived. Overall, 3136 participants were randomized (1572 gepotidacin, 1564 nitrofurantoin). Mean (median) baseline symptom scores for gepotidacin and nitrofurantoin arms were 7.1 (7.0) and 7.2 (7.0), respectively; at OT, this decreased to 3.6 (3.0) for both arms. At the OT visit, >80% of participants had clinical improvement/resolution. Among those with baseline symptoms affecting everyday activities (moderate or severe), 53.2% (728/1369) assigned gepotidacin and 53.6% (738/1377) assigned nitrofurantoin reported at OT that symptoms no longer affected everyday activities (mild or absent); at TOC, these percentages were 93.8% (1232/1313) and 93.3% (1254/1344), respectively. Gepotidacin and nitrofurantoin provide meaningful and similar early relief from uUTI symptoms.31:T974,Abstract Background Uncomplicated urinary tract infections (uUTIs) can cause distressing symptoms seriously impacting daily activities. Early symptom relief during treatment, though fundamental to patients, is often overlooked in clinical trials. Gepotidacin, a new antibacterial agent, was noninferior to the first-line treatment nitrofurantoin in two randomized controlled trials (EAGLE-2 [NCT04020341] and EAGLE-3 [NCT04187144]). The current analysis utilized pooled data from these two trials to evaluate symptom responses during and after treatment in participants with uUTI. Methods Participants were aged ≥12 years with at least two uUTI symptoms, urinary nitrite and/or pyuria, and no complicating factors. Participants were randomized 1:1 to oral gepotidacin (1500 mg) or nitrofurantoin (100 mg), both taken twice daily for 5 days. At baseline (Day 1), on-therapy (OT; Day 2–4), and test-of-cure (TOC; Day 10–13) visits, urinary symptoms were assessed (0–3; none–severe) from which a total score (0–12) was derived. Results Overall, 3136 participants were randomized (1572 gepotidacin, 1564 nitrofurantoin). Mean (median) baseline symptom scores for gepotidacin and nitrofurantoin arms were 7.1 (7.0) and 7.2 (7.0), respectively; at OT, this decreased to 3.6 (3.0) for both arms. At the OT visit, >80% of participants had clinical improvement/resolution. Among those with baseline symptoms affecting everyday activities (moderate or severe), 53.2% (728/1369) assigned gepotidacin and 53.6% (738/1377) assigned nitrofurantoin reported at OT that symptoms no longer affected everyday activities (mild or absent); at TOC, these percentages were 93.8% (1232/1313) and 93.3% (1254/1344), respectively. Conclusions Gepotidacin and nitrofurantoin provide meaningful and similar early relief from uUTI symptoms. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Uncomplicated Urinary Tract Infection: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Uncomplicated Urinary Tract Infection (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Uncomplicated%20Urinary%20Tract%20Infection\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Uncomplicated Urinary Tract Infection\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Uncomplicated%20Urinary%20Tract%20Infection\"}]}}"}}]],["$","$L2f",null,{"title":"Uncomplicated Urinary Tract Infection: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Uncomplicated Urinary Tract Infection with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.3399/bjgp.2025.0678","pmid":"42392834","title":"Recording of Pharmacy First consultations in general practice records in England: an observational study of the service's first year using OpenSAFELY","journal_title":"British Journal of General Practice","journal_issn":"0960-1643","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.3399/bjgp.2025.0678","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-08T13:26:40.267Z","updated_at":"2026-07-08T13:26:40.267Z","tags":[{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"category","value":"Primary Health Care","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Acute Otitis Media","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Acute Pharyngitis","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Acute Sinusitis","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Herpes Zoster","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Impetigo","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Infected Insect Bites","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"condition","value":"Uncomplicated Urinary Tract Infection","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"modality","value":"Community Pharmacy Service","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"sample_size","value":"n=26142380","value_numeric":26142380},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"warning","value":"Level of evidence assigned as 3 (retrospective cohort using routine EHR data); no control group or causal inference was attempted — the study is purely descriptive.","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"warning","value":"OpenSAFELY-TPP covers approximately 40% of England's GP-registered population and excludes EMIS-system practices; findings may not fully represent urban or London populations.","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"warning","value":"The sample size tag reflects the total registered OpenSAFELY-TPP population used as the denominator; actual Pharmacy First users were 340,710 patients across 402,165 consultations.","value_numeric":null},{"paper_doi":"10.3399/bjgp.2025.0678","tag_type":"warning","value":"The study period (Jan 2024–Jan 2025) predates the October 2025 contractual mandate for GP Connect, so recording rates reported here are likely lower than current practice.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used OpenSAFELY-TPP to describe how Pharmacy First community pharmacy consultations were recorded in GP records during the service's first year (31 Jan 2024 – 30 Jan 2025), covering ~26 million registered patients across 2,540 English GP practices.","key_result":"402,165 Pharmacy First consultations were recorded for 340,710 patients — just 11–24% of the expected total based on NHS BSA reimbursement data. By January 2025, only 36.3% of recorded consultations included a clinical condition, medication, or both (rising to 53.7% when restricted to the recommended SNOMED CT code). Acute pharyngitis (28.9%) and uncomplicated UTI (28%) were the most common conditions. Users were predominantly female (67.3%), younger (59.3% under 40), and more deprived (25.4% in the most deprived IMD quintile).","limitations":"- OpenSAFELY-TPP covers ~40% of England's GP population, with London underrepresented, limiting urban generalisability.\n- GP records only capture consultations successfully transferred electronically; gaps likely reflect technical failures (e.g., GP Connect disruptions during industrial action) rather than true service non-use.\n- Clinical condition recording was not mandatory under the service specification, so absence of structured codes does not confirm absence of clinical assessment.","practice_takeaway":"GPs should be aware that Pharmacy First consultation summaries may be missing or lack coded clinical details in their systems — checking for incomplete records is important for safe clinical handover. Ensuring GP Connect: Update Record is enabled (now a contractual requirement since October 2025) is essential for complete data transfer."}},{"doi":"10.1093/cid/ciaf722","pmid":"41495938","title":"Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies","journal_title":"Clinical Infectious Diseases","journal_issn":"1058-4838","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.1093/cid/ciaf722","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1093/cid/ciaf722","days":"7","issn":"1058-4838","rank":"10","field":"Clinical Medicine","score":"15","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1093/cid/ciaf722","title":"Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","methods":"","results":"Overall, 3136 participants were randomized (1572 gepotidacin, 1564 nitrofurantoin). Mean (median) baseline symptom scores for gepotidacin and nitrofurantoin arms were 7.1 (7.0) and 7.2 (7.0), respectively; at OT, this decreased to 3.6 (3.0) for both arms. At the OT visit, >80% of participants had clinical improvement/resolution. Among those with baseline symptoms affecting everyday activities (moderate or severe), 53.2% (728/1369) assigned gepotidacin and 53.6% (738/1377) assigned nitrofurantoin reported at OT that symptoms no longer affected everyday activities (mild or absent); at TOC, these percentages were 93.8% (1232/1313) and 93.3% (1254/1344), respectively.","abstract":"$30","keywords":["Urinary tract infection","antibacterials","gepotidacin","uncomplicated UTI"],"pubmed_id":"41495938","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1093/cid/ciaf722","URL":"https://doi.org/10.1093/cid/ciaf722","ISSN":["1058-4838","1537-6591"],"link":[{"URL":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf722/66286532/ciaf722.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf722/66286532/ciaf722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies"],"author":[{"given":"Amanda J","family":"Sheets","sequence":"first","affiliation":[{"name":"GSK, Collegeville , PA ,"}]},{"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[{"name":"GSK , London ,"}]},{"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Michigan , Ann Arbor, MI ,"}]},{"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Infectious Diseases, and Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ ,"}]},{"given":"Caroline","family":"Perry","sequence":"additional","affiliation":[{"name":"GSK, Collegeville , PA ,"}]},{"given":"Helen","family":"Millns","sequence":"additional","affiliation":[{"name":"GSK, Stevenage ,"}]},{"given":"Jazmín","family":"Díaz-Regañón","sequence":"additional","affiliation":[{"name":"GSK , Madrid ,"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[{"name":"GSK , London ,"}]}],"issued":{"date-parts":[[2026,1,6]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2026-01-06T12:28:26Z","timestamp":1767702506000,"date-parts":[[2026,1,6]]},"indexed":{"date-time":"2026-01-07T05:41:49Z","timestamp":1767764509410,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":1,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf722/8415988"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T05:11:22Z","timestamp":1767762682000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"published":{"date-parts":[[2026,1,6]]},"publisher":"Oxford University Press (OUP)","reference":null,"short-title":[],"article-number":"ciaf722","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Clinical Infectious Diseases"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,6]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/cid/ciaf722","is_oa":true,"title":"Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studies","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-06","best_oa_location":{"url":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf722/66286532/ciaf722.pdf","pmh_id":null,"url_for_pdf":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf722/66286532/ciaf722.pdf","url_for_landing_page":"https://doi.org/10.1093/cid/ciaf722"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-15T20:51:27.064Z","tags":[{"paper_doi":"10.1093/cid/ciaf722","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"condition","value":"Uncomplicated Urinary Tract Infection","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"generic","value":"gepotidacin","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"generic","value":"nitrofurantoin","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"sample_size","value":"n=3136","value_numeric":3136},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"study_design","value":"Pooled Analysis","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"warning","value":"Pooled analysis of two randomized trials; design classification as a single study may be imperfect.","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"warning","value":"Sex distribution and other baseline characteristics are not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf722","tag_type":"warning","value":"The on-therapy improvement rate is reported only as \">80%,\" without a precise percentage.","value_numeric":null}],"summaries":{"what_studied":"Pooled analysis of two phase 3 randomized trials (EAGLE-2 and EAGLE-3; n=3136) comparing 5 days of oral gepotidacin 1500 mg BID versus nitrofurantoin 100 mg BID in patients aged ≥12 years with uncomplicated UTI. Patient-reported urinary symptoms were scored at baseline (Day 1), on-therapy (Days 2–4), and test-of-cure (Days 10–13).","key_result":"Mean symptom scores fell from 7.1–7.2 at baseline to 3.6 by Days 2–4 in both arms, and >80% had clinical improvement/resolution at the on-therapy visit. Among those with baseline symptoms that limited daily activities, 53.2% (728/1369) vs 53.6% (738/1377) reported no longer activity-limiting by Days 2–4, increasing to 93.8% (1232/1313) vs 93.3% (1254/1344) at Days 10–13.","practice_takeaway":"Expect similar early symptom relief with 5-day gepotidacin or nitrofurantoin for uncomplicated UTI, with most patients improved by Days 2–4 and over 90% with activity-limiting symptoms improved by Days 10–13. Either regimen provides comparable patient-reported relief during treatment."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Uncomplicated Urinary Tract Infection"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Uncomplicated Urinary Tract Infection"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Uncomplicated Urinary Tract Infection"}}}]]

Papers